Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2008-07-08

AUTHORS

Asma Sultana, Paula Ghaneh, David Cunningham, Naureen Starling, John P Neoptolemos, Catrin Tudur Smith

ABSTRACT

BackgroundRecent meta-analyses have found a survival advantage with gemcitabine based combinations over single agent gemcitabine in patients with advanced pancreatic cancer. There is paucity of evidence in the form of direct head-to-head randomised controlled trials to determine which combinations are to be preferred.MethodUsing the adjusted indirect comparison method proposed by Bucher et al, we have assessed randomised controlled trials of four gemcitabine based combinations namely gemcitabine plus a platinum compound or 5-fluorouracil or irinotecan or capecitabine.ResultsNo particular combination was significantly superior to another, but the indirect evidence suggests some important trends.ConclusionThe strongest trends on indirect comparison are towards favouring gemcitabine plus capecitabine or gemcitabine plus a platinum compound over gemcitabine plus irinotecan, and to a lesser degree, over gemcitabine plus 5-fluorouracil. More... »

PAGES

192

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1471-2407-8-192

DOI

http://dx.doi.org/10.1186/1471-2407-8-192

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1016928860

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18611273


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimetabolites, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Camptothecin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Capecitabine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials, Phase III as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Irinotecan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Meta-Analysis as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pancreatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Platinum", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proportional Hazards Models", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "CRUK Liverpool Cancer Trials Unit, Cancer Research Centre, 200 London Road, L3 9TA, Liverpool, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "CRUK Liverpool Cancer Trials Unit, Cancer Research Centre, 200 London Road, L3 9TA, Liverpool, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sultana", 
        "givenName": "Asma", 
        "id": "sg:person.01246775112.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01246775112.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "CRUK Liverpool Cancer Trials Unit, Cancer Research Centre, 200 London Road, L3 9TA, Liverpool, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "CRUK Liverpool Cancer Trials Unit, Cancer Research Centre, 200 London Road, L3 9TA, Liverpool, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ghaneh", 
        "givenName": "Paula", 
        "id": "sg:person.07372440237.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07372440237.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Royal Marsden Hospital, Downs Road, SM2 5PT, Sutton, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/grid.424926.f", 
          "name": [
            "Department of Medicine, Royal Marsden Hospital, Downs Road, SM2 5PT, Sutton, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cunningham", 
        "givenName": "David", 
        "id": "sg:person.01320161130.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320161130.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Royal Marsden Hospital, Downs Road, SM2 5PT, Sutton, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/grid.424926.f", 
          "name": [
            "Department of Medicine, Royal Marsden Hospital, Downs Road, SM2 5PT, Sutton, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Starling", 
        "givenName": "Naureen", 
        "id": "sg:person.01136565472.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136565472.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "CRUK Liverpool Cancer Trials Unit, Cancer Research Centre, 200 London Road, L3 9TA, Liverpool, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "CRUK Liverpool Cancer Trials Unit, Cancer Research Centre, 200 London Road, L3 9TA, Liverpool, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Neoptolemos", 
        "givenName": "John P", 
        "id": "sg:person.0750565077.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750565077.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre for Medical Statistics and Health Evaluation, University of Liverpool, Shelley's Cottage, Brownlow Street, L69 3GS, Liverpool, UK", 
          "id": "http://www.grid.ac/institutes/grid.10025.36", 
          "name": [
            "CRUK Liverpool Cancer Trials Unit, Cancer Research Centre, 200 London Road, L3 9TA, Liverpool, UK", 
            "Centre for Medical Statistics and Health Evaluation, University of Liverpool, Shelley's Cottage, Brownlow Street, L69 3GS, Liverpool, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Smith", 
        "givenName": "Catrin Tudur", 
        "id": "sg:person.016064124243.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016064124243.23"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.bjc.6602640", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018777234", 
          "https://doi.org/10.1038/sj.bjc.6602640"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6603301", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026926621", 
          "https://doi.org/10.1038/sj.bjc.6603301"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2008-07-08", 
    "datePublishedReg": "2008-07-08", 
    "description": "BackgroundRecent meta-analyses have found a survival advantage with gemcitabine based combinations over single agent gemcitabine in patients with advanced pancreatic cancer. There is paucity of evidence in the form of direct head-to-head randomised controlled trials to determine which combinations are to be preferred.MethodUsing the adjusted indirect comparison method proposed by Bucher et al, we have assessed randomised controlled trials of four gemcitabine based combinations namely gemcitabine plus a platinum compound or 5-fluorouracil or irinotecan or capecitabine.ResultsNo particular combination was significantly superior to another, but the indirect evidence suggests some important trends.ConclusionThe strongest trends on indirect comparison are towards favouring gemcitabine plus capecitabine or gemcitabine plus a platinum compound over gemcitabine plus irinotecan, and to a lesser degree, over gemcitabine plus 5-fluorouracil.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/1471-2407-8-192", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2780638", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "8"
      }
    ], 
    "keywords": [
      "single-agent gemcitabine", 
      "advanced pancreatic cancer", 
      "paucity of evidence", 
      "platinum compounds", 
      "indirect comparison method", 
      "Bucher et al", 
      "combination chemotherapy", 
      "pancreatic cancer", 
      "agent gemcitabine", 
      "survival advantage", 
      "indirect comparison", 
      "gemcitabine", 
      "direct head", 
      "capecitabine", 
      "trials", 
      "indirect evidence", 
      "lesser degree", 
      "strong trend", 
      "chemotherapy", 
      "patients", 
      "irinotecan", 
      "BackgroundRecent", 
      "cancer", 
      "head", 
      "evidence", 
      "paucity", 
      "combination", 
      "MethodUsing", 
      "comparison", 
      "trends", 
      "compounds", 
      "particular combination", 
      "degree", 
      "form", 
      "method", 
      "et al", 
      "comparison method", 
      "important trends", 
      "advantages", 
      "al"
    ], 
    "name": "Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison", 
    "pagination": "192", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1016928860"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1471-2407-8-192"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18611273"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1471-2407-8-192", 
      "https://app.dimensions.ai/details/publication/pub.1016928860"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:35", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_477.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/1471-2407-8-192"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-8-192'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-8-192'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-8-192'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-8-192'


 

This table displays all metadata directly associated to this object as RDF triples.

220 TRIPLES      21 PREDICATES      84 URIs      74 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1471-2407-8-192 schema:about N01c9dc5e98434420867cdbde17a38f34
2 N0809ee1a7a304e2b9f9b71be92528964
3 N1cea14e5a86d455886c568edb7840658
4 N28965e9ba5564e3a98cffde528ef9209
5 N5cdc024f3a4540e8b9c48aa1b2f0f735
6 N6205a9c9195c4ee9ae4bf83cf01371ea
7 N7661c242c82947c3bcde11ad2f6d51f1
8 N7c98f881e898472aa4f8667946cd5223
9 N8dcbfc2b38eb4129ace4e924cce640fa
10 N959d97b9ceeb49dcb0befb1f9f2d15c8
11 N9b9aac3c5d6c483fa2a5e10608024b3f
12 Na3ae7c4dfecf4e088a539d423d4ca533
13 Nb21801fe61f049248cdd22990c04c2ea
14 Nc1b514d630e3426bb60c0c07c2406863
15 Nd87ba9448f1a4aa789d80e63f8fbc3fa
16 Ne1c14253d1b5424aab92b5922c032e8b
17 Ne4ede894ffa041db9ebc3c7d21b9b4d6
18 anzsrc-for:11
19 anzsrc-for:1112
20 schema:author Nf8f7465f6a6e41298f90f6c7db4d0eef
21 schema:citation sg:pub.10.1038/sj.bjc.6602640
22 sg:pub.10.1038/sj.bjc.6603301
23 schema:datePublished 2008-07-08
24 schema:datePublishedReg 2008-07-08
25 schema:description BackgroundRecent meta-analyses have found a survival advantage with gemcitabine based combinations over single agent gemcitabine in patients with advanced pancreatic cancer. There is paucity of evidence in the form of direct head-to-head randomised controlled trials to determine which combinations are to be preferred.MethodUsing the adjusted indirect comparison method proposed by Bucher et al, we have assessed randomised controlled trials of four gemcitabine based combinations namely gemcitabine plus a platinum compound or 5-fluorouracil or irinotecan or capecitabine.ResultsNo particular combination was significantly superior to another, but the indirect evidence suggests some important trends.ConclusionThe strongest trends on indirect comparison are towards favouring gemcitabine plus capecitabine or gemcitabine plus a platinum compound over gemcitabine plus irinotecan, and to a lesser degree, over gemcitabine plus 5-fluorouracil.
26 schema:genre article
27 schema:isAccessibleForFree true
28 schema:isPartOf N68d31dcf6927465d8f695eaf47e298b7
29 Nacaa4a1ad66e426086e225a6fb8c15e9
30 sg:journal.1024632
31 schema:keywords BackgroundRecent
32 Bucher et al
33 MethodUsing
34 advanced pancreatic cancer
35 advantages
36 agent gemcitabine
37 al
38 cancer
39 capecitabine
40 chemotherapy
41 combination
42 combination chemotherapy
43 comparison
44 comparison method
45 compounds
46 degree
47 direct head
48 et al
49 evidence
50 form
51 gemcitabine
52 head
53 important trends
54 indirect comparison
55 indirect comparison method
56 indirect evidence
57 irinotecan
58 lesser degree
59 method
60 pancreatic cancer
61 particular combination
62 patients
63 paucity
64 paucity of evidence
65 platinum compounds
66 single-agent gemcitabine
67 strong trend
68 survival advantage
69 trends
70 trials
71 schema:name Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison
72 schema:pagination 192
73 schema:productId N73e6d723ceaf4ed08504c677430bd26a
74 N880614dcc69d4b2d95cdcae049425ce0
75 Naeb9ad70b3754dbbb748bb97cb373e19
76 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016928860
77 https://doi.org/10.1186/1471-2407-8-192
78 schema:sdDatePublished 2022-10-01T06:35
79 schema:sdLicense https://scigraph.springernature.com/explorer/license/
80 schema:sdPublisher Nf5e405a31b674e49ae25edebc3269b09
81 schema:url https://doi.org/10.1186/1471-2407-8-192
82 sgo:license sg:explorer/license/
83 sgo:sdDataset articles
84 rdf:type schema:ScholarlyArticle
85 N01c9dc5e98434420867cdbde17a38f34 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Antineoplastic Combined Chemotherapy Protocols
87 rdf:type schema:DefinedTerm
88 N0809ee1a7a304e2b9f9b71be92528964 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Humans
90 rdf:type schema:DefinedTerm
91 N141ce8b2cd664b6f855ede2a17736a90 rdf:first sg:person.07372440237.86
92 rdf:rest Nfcba33a67b3f47e7bdc1ddd26da4bb4d
93 N1bbe492416964eb98bab5444c5994818 rdf:first sg:person.01136565472.17
94 rdf:rest N2da3b778586243d4a8966d0c51ed8653
95 N1cea14e5a86d455886c568edb7840658 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Meta-Analysis as Topic
97 rdf:type schema:DefinedTerm
98 N28965e9ba5564e3a98cffde528ef9209 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Camptothecin
100 rdf:type schema:DefinedTerm
101 N2da3b778586243d4a8966d0c51ed8653 rdf:first sg:person.0750565077.18
102 rdf:rest Na4179346c38f4bc6a7a6173d438e6350
103 N5cdc024f3a4540e8b9c48aa1b2f0f735 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Survival Analysis
105 rdf:type schema:DefinedTerm
106 N6205a9c9195c4ee9ae4bf83cf01371ea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Proportional Hazards Models
108 rdf:type schema:DefinedTerm
109 N68d31dcf6927465d8f695eaf47e298b7 schema:issueNumber 1
110 rdf:type schema:PublicationIssue
111 N73e6d723ceaf4ed08504c677430bd26a schema:name doi
112 schema:value 10.1186/1471-2407-8-192
113 rdf:type schema:PropertyValue
114 N7661c242c82947c3bcde11ad2f6d51f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Pancreatic Neoplasms
116 rdf:type schema:DefinedTerm
117 N7c98f881e898472aa4f8667946cd5223 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Antimetabolites, Antineoplastic
119 rdf:type schema:DefinedTerm
120 N880614dcc69d4b2d95cdcae049425ce0 schema:name pubmed_id
121 schema:value 18611273
122 rdf:type schema:PropertyValue
123 N8dcbfc2b38eb4129ace4e924cce640fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Clinical Trials, Phase III as Topic
125 rdf:type schema:DefinedTerm
126 N959d97b9ceeb49dcb0befb1f9f2d15c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Deoxycytidine
128 rdf:type schema:DefinedTerm
129 N9b9aac3c5d6c483fa2a5e10608024b3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Randomized Controlled Trials as Topic
131 rdf:type schema:DefinedTerm
132 Na3ae7c4dfecf4e088a539d423d4ca533 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Capecitabine
134 rdf:type schema:DefinedTerm
135 Na4179346c38f4bc6a7a6173d438e6350 rdf:first sg:person.016064124243.23
136 rdf:rest rdf:nil
137 Nacaa4a1ad66e426086e225a6fb8c15e9 schema:volumeNumber 8
138 rdf:type schema:PublicationVolume
139 Naeb9ad70b3754dbbb748bb97cb373e19 schema:name dimensions_id
140 schema:value pub.1016928860
141 rdf:type schema:PropertyValue
142 Nb21801fe61f049248cdd22990c04c2ea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Drug Administration Schedule
144 rdf:type schema:DefinedTerm
145 Nc1b514d630e3426bb60c0c07c2406863 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Treatment Outcome
147 rdf:type schema:DefinedTerm
148 Nd87ba9448f1a4aa789d80e63f8fbc3fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Platinum
150 rdf:type schema:DefinedTerm
151 Ne1c14253d1b5424aab92b5922c032e8b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Fluorouracil
153 rdf:type schema:DefinedTerm
154 Ne4ede894ffa041db9ebc3c7d21b9b4d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Irinotecan
156 rdf:type schema:DefinedTerm
157 Nf5e405a31b674e49ae25edebc3269b09 schema:name Springer Nature - SN SciGraph project
158 rdf:type schema:Organization
159 Nf8f7465f6a6e41298f90f6c7db4d0eef rdf:first sg:person.01246775112.38
160 rdf:rest N141ce8b2cd664b6f855ede2a17736a90
161 Nfcba33a67b3f47e7bdc1ddd26da4bb4d rdf:first sg:person.01320161130.16
162 rdf:rest N1bbe492416964eb98bab5444c5994818
163 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
164 schema:name Medical and Health Sciences
165 rdf:type schema:DefinedTerm
166 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
167 schema:name Oncology and Carcinogenesis
168 rdf:type schema:DefinedTerm
169 sg:grant.2780638 http://pending.schema.org/fundedItem sg:pub.10.1186/1471-2407-8-192
170 rdf:type schema:MonetaryGrant
171 sg:journal.1024632 schema:issn 1471-2407
172 schema:name BMC Cancer
173 schema:publisher Springer Nature
174 rdf:type schema:Periodical
175 sg:person.01136565472.17 schema:affiliation grid-institutes:grid.424926.f
176 schema:familyName Starling
177 schema:givenName Naureen
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136565472.17
179 rdf:type schema:Person
180 sg:person.01246775112.38 schema:affiliation grid-institutes:None
181 schema:familyName Sultana
182 schema:givenName Asma
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01246775112.38
184 rdf:type schema:Person
185 sg:person.01320161130.16 schema:affiliation grid-institutes:grid.424926.f
186 schema:familyName Cunningham
187 schema:givenName David
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320161130.16
189 rdf:type schema:Person
190 sg:person.016064124243.23 schema:affiliation grid-institutes:grid.10025.36
191 schema:familyName Smith
192 schema:givenName Catrin Tudur
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016064124243.23
194 rdf:type schema:Person
195 sg:person.07372440237.86 schema:affiliation grid-institutes:None
196 schema:familyName Ghaneh
197 schema:givenName Paula
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07372440237.86
199 rdf:type schema:Person
200 sg:person.0750565077.18 schema:affiliation grid-institutes:None
201 schema:familyName Neoptolemos
202 schema:givenName John P
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750565077.18
204 rdf:type schema:Person
205 sg:pub.10.1038/sj.bjc.6602640 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018777234
206 https://doi.org/10.1038/sj.bjc.6602640
207 rdf:type schema:CreativeWork
208 sg:pub.10.1038/sj.bjc.6603301 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026926621
209 https://doi.org/10.1038/sj.bjc.6603301
210 rdf:type schema:CreativeWork
211 grid-institutes:None schema:alternateName CRUK Liverpool Cancer Trials Unit, Cancer Research Centre, 200 London Road, L3 9TA, Liverpool, UK
212 schema:name CRUK Liverpool Cancer Trials Unit, Cancer Research Centre, 200 London Road, L3 9TA, Liverpool, UK
213 rdf:type schema:Organization
214 grid-institutes:grid.10025.36 schema:alternateName Centre for Medical Statistics and Health Evaluation, University of Liverpool, Shelley's Cottage, Brownlow Street, L69 3GS, Liverpool, UK
215 schema:name CRUK Liverpool Cancer Trials Unit, Cancer Research Centre, 200 London Road, L3 9TA, Liverpool, UK
216 Centre for Medical Statistics and Health Evaluation, University of Liverpool, Shelley's Cottage, Brownlow Street, L69 3GS, Liverpool, UK
217 rdf:type schema:Organization
218 grid-institutes:grid.424926.f schema:alternateName Department of Medicine, Royal Marsden Hospital, Downs Road, SM2 5PT, Sutton, Surrey, UK
219 schema:name Department of Medicine, Royal Marsden Hospital, Downs Road, SM2 5PT, Sutton, Surrey, UK
220 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...